. Safety and effectiveness of the anti-amyloid monoclonal antibody (mAb) drug lecanemab for early Alzheimer's disease: The pharmacovigilance perspective. Br J Clin Pharmacol. 2025 Mar 6; Epub 2025 Mar 6 PubMed.

Recommends

Please login to recommend the paper.

Comments

No Available Comments

Make a Comment

To make a comment you must login or register.